Cat. No：GM-C21622
Product：STING Reporter THP1(H_STING KO) Cell Line
Cat. No：GM-C21622
Product：STING Reporter THP1(H_STING KO) Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+ 0.05 mM 2-Me+0.5 μg/mL Puromycin+2 μg/mL Blasticidin+400 μg/mL G418
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS +1% P.S
STING (Stimulator of interferon genes) can recognize cyclic dinucleotides (CDN) in the cytoplasm, and then activate the innate immune response through the cGAS-STING pathway. Agonists targeting the STING pathway are currently receiving significant attention from researchers in areas such as cancer, obesity, viral infections, liver damage, and disorders in glucose and lipid metabolism. The main mechanism of STING in tumors is its involvement in T cell-mediated tumor immune response. Activation of the cGAS-STING pathway has been found to effectively inhibit cancer cell metastasis in various cancer-related diseases such as colon cancer, melanoma, and telomerase deficiency.
Genomeditech's STING KO Reporter THP1 Cell Line is a luciferase reporter cell line constructed based on the STING/TBK1/IRF3 signaling pathway. This cell line has the STING gene knocked out from Genomeditech's STING Reporter THP1 Cell Line (Genomeditech/GM-C21640), making it unable to bind to CDN and activate the cGAS-STING pathway. However, IFNα can still activate the JAK-STAT pathway, leading to the expression of luciferase. Luciferase readings represent the activation effect of the signaling pathway and can be used as a control cell for the STING Reporter THP1 Cell Line to verify the binding specificity of CDN drugs.
Cat. No：GM-C21622
Product：STING Reporter THP1(H_STING KO) Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+ 0.05 mM 2-Me+0.5 μg/mL Puromycin+2 μg/mL Blasticidin+400 μg/mL G418
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640+1% FBS +1% P.S
STING (Stimulator of interferon genes) can recognize cyclic dinucleotides (CDN) in the cytoplasm, and then activate the innate immune response through the cGAS-STING pathway. Agonists targeting the STING pathway are currently receiving significant attention from researchers in areas such as cancer, obesity, viral infections, liver damage, and disorders in glucose and lipid metabolism. The main mechanism of STING in tumors is its involvement in T cell-mediated tumor immune response. Activation of the cGAS-STING pathway has been found to effectively inhibit cancer cell metastasis in various cancer-related diseases such as colon cancer, melanoma, and telomerase deficiency.
Genomeditech's STING KO Reporter THP1 Cell Line is a luciferase reporter cell line constructed based on the STING/TBK1/IRF3 signaling pathway. This cell line has the STING gene knocked out from Genomeditech's STING Reporter THP1 Cell Line (Genomeditech/GM-C21640), making it unable to bind to CDN and activate the cGAS-STING pathway. However, IFNα can still activate the JAK-STAT pathway, leading to the expression of luciferase. Luciferase readings represent the activation effect of the signaling pathway and can be used as a control cell for the STING Reporter THP1 Cell Line to verify the binding specificity of CDN drugs.
